Search

Pharming Group NV

Cerrado

0.717 -2.45

Resumen

Variación precio

24h

Actual

Mínimo

0.71

Máximo

0.739

Métricas clave

By Trading Economics

Ingresos

259K

-959K

Ventas

756K

75M

BPA

0.005

Margen de beneficios

-1.281

EBITDA

1.9M

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

534M

Apertura anterior

3.17

Cierre anterior

0.717

Pharming Group NV Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 abr 2025, 23:04 UTC

Principales Noticias

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 abr 2025, 22:40 UTC

Principales Movimientos del Mercado

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 abr 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 abr 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 abr 2025, 23:43 UTC

Charlas de Mercado

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 abr 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 abr 2025, 22:22 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 abr 2025, 21:43 UTC

Principales Noticias
Ganancias

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 abr 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 abr 2025, 20:43 UTC

Charlas de Mercado

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 abr 2025, 20:34 UTC

Principales Noticias

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 abr 2025, 20:23 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 20:15 UTC

Adquisiciones, fusiones, absorciones

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 abr 2025, 19:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 abr 2025, 19:55 UTC

Charlas de Mercado

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 abr 2025, 19:21 UTC

Charlas de Mercado

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 abr 2025, 19:15 UTC

Charlas de Mercado

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 abr 2025, 18:45 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:45 UTC

Charlas de Mercado

Gold Drops In Tariff Fallout -- Market Talk

3 abr 2025, 18:39 UTC

Charlas de Mercado

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 abr 2025, 18:38 UTC

Principales Noticias

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 abr 2025, 18:30 UTC

Principales Noticias

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 abr 2025, 18:20 UTC

Charlas de Mercado

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 abr 2025, 18:18 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

3 abr 2025, 18:17 UTC

Charlas de Mercado

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 abr 2025, 18:04 UTC

Charlas de Mercado

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 abr 2025, 17:55 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Pharming Group NV previsión

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.